Merus NV Stock News

Merus N.V. is a biotech company developing novel bispecific antibodies, with two drugs in development for unmet needs in head and neck cancer and solid tumors. Petosemtamab, targeting EGFR and LGR5, s

The mean of analysts' price targets for Merus N.V. (MRUS) points to an 87.7% upside in the stock.

Merus N.V. (MRUS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

MCLA-129 in combination with chemotherapy in 2L+ EGFRm NSCLC planned to initiate 1Q24 MCLA-129 in combination with chemotherapy in 2L+ EGFRm NSCLC planned to initiate 1Q24

-  Oral presentation on MCLA-129 in combination with osimertinib as first line therapy, and in previously treated, NSCLC on Sunday, December 3 at 9:40 a.m. SGT

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodie

Merus N.V. (MRUS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 15, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, fu

Merus stock has cooled down after a strong rally, but long-term investors are sitting on a 47% gain since January. The company's pipeline includes promising clinical assets, but sentiment towards the

Merus N.V. (MRUS) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to loss of $0.13 per share a year ago.

Shares of Merus NV MRUS, +3.02% rallied as much as 10% in the extended session Thursday after the pharma company said the U.S. Food and Drug Administration has granted one of its cancer treatments a b

Stock screeners can help investors identify stocks to buy based on a variety of criteria. In fact, one helpful predictor of stock price growth can be found with analyst ratings.

Does Merus N.V. (MRUS) have what it takes to be a top stock pick for momentum investors?

Merus N.V. (MRUS) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to loss of $0.43 per share a year ago.

Merus N.V. develops bispecific and trispecific antibodies for cancer. They have deals with an array of big pharma.